Previous 10 | Next 10 |
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology product candidate, THOR-707, will be presented...
SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the details of a scientific presentation characterizing THOR-809, a Synthorin™ fo...
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at the H.C. Wainwright 21 st Annual Global Investment Conferenc...
Synthorx (NASDAQ: THOR ): Q2 GAAP EPS of -$0.39 misses by $0.01 . More news on: Synthorx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update for the second quarter ended June 30, 201...
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced today it has opened HAMMER, a global, Phase 1/2, first-in-human clinical trial of THOR-707, wit...
I’ve been what I’d call “cautiously bullish” on Nektar ( NKTR ) and its lead drug bempegaldesleukin (formerly known as NKTR-214, I’m going with “bempeg” for short); while the idea of a safer form of IL-2 to accompany PD-1 antibodies and other ...
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the Company will presen...
SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company discovering and developing optimized biologics for cancer and autoimmune disorders, today announced company researchers will present preclinical data demonstrating the potential safety and ant...
Synthorx (NASDAQ: THOR ): Q1 GAAP EPS of -$0.35 misses by $0.07 . More news on: Synthorx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
AMC Theatres (NYSE: AMC) has reported domestic and global success on its busiest weekend of 2022 so far from Thursday July 7th through Sunday July 10th. This was led by the opening weekend of Thor: Love and Thunder as the box office was propelled by several summer blockb...
Thor Industries (NYSE: THOR ) , a recreational vehicle maker, reported better-than-expected quarterly earnings Wednesday amid high demand for its products. The manufacturer reported earnings of USD6.32 per share, compared to the expected USD...
Nigeria is known as one of Africa’s largest and oldest oil and natural gas producers – the sector accounts for more than 90% of the country’s exports, and 80% of the federal government’s revenue. But until recently, the mining sector has been on the...